Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LGVN stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Longeveron’s ongoing clinical developments and financial strategy. The company is making significant progress with its lead product, Laromestrocel, particularly in the ELPIS II trial for treating hypoplastic left heart syndrome (HLHS). The trial has completed enrollment, and the anticipated topline results in 2026 could potentially support a Biologics License Application (BLA) filing by the end of 2026, positioning the company for potential approval in 2027.
Additionally, Longeveron is expanding its research into pediatric dilated cardiomyopathy and is seeking partnerships for Alzheimer’s disease applications, which could further enhance its market potential. Despite a recent equity financing that led to dilution and a lowered price target, the company’s strategic moves and promising clinical data underpin the Buy rating. The financial outlook remains stable, with sufficient funding projected into 2025, supported by grant funding for ongoing studies, which offsets some expenses and reduces financial risk.
According to TipRanks, Okunewitch is an analyst with an average return of -13.2% and a 34.68% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as ATAI Life Sciences, Lineage Therap, and Ocugen.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $3.00 price target.